Quarterly ResultMay 14, 2026, 04:19 PM
Co-Diagnostics Reports Q1 Net Loss $9.14M; Going Concern Doubt
AI Summary
Co-Diagnostics, Inc. reported a net loss of $9.14 million for Q1 2026, an increase from $7.53 million in Q1 2025. The company's management has concluded that substantial doubt exists about its ability to continue as a going concern for the next 12 months, citing dependence on future financing and profitable operations. Despite a significant increase in product revenue to $145,954, operating expenses also rose, leading to a larger loss from operations. The company raised $4.33 million through an at-the-market offering to support its capital requirements.
Key Highlights
- Substantial doubt exists about Co-Diagnostics' ability to continue as a going concern for the next 12 months.
- Q1 2026 net loss increased to $9.14 million, up from $7.53 million in Q1 2025.
- Product revenue for Q1 2026 rose to $145,954, compared to $50,277 in Q1 2025.
- Cash and cash equivalents decreased to $8.23 million as of March 31, 2026, from $11.88 million at December 31, 2025.
- Total operating expenses increased to $9.16 million in Q1 2026 from $8.58 million in Q1 2025.
- Research and development expenses rose to $5.93 million in Q1 2026, up from $4.87 million in Q1 2025.
- Net cash used in operating activities was $7.85 million for Q1 2026.
- The company raised $4.33 million from the issuance of common stock through an at-the-market offering in Q1 2026.
Price Impact
More from CODX